Life after GWAS comments
Allen Roses, director of the Deane Drug Discovery Institute at Duke University, noted that GWAS has “largely disappointed its most enthusiastic proponents Continue reading Forget about genes V
Life after GWAS comments
Allen Roses, director of the Deane Drug Discovery Institute at Duke University, noted that GWAS has “largely disappointed its most enthusiastic proponents Continue reading Forget about genes V
Genowatch (paper|website) is doing pretty well by annotating large SNP sets that would require otherwise numerous hours to map their position on genes, biological function and pathways. Continue reading SNP batch annotation of GWAs
The experts in the field will immediately notice what I am suggesting here – an improved GWA plot that does not take into account p values alone but also effect sizes. I was experimenting some time with smile plots but finally ended with this bubble plot. Bubble size for 0.5<OR>2 is set to a minimum while all other ORs get increasing bubbles (BTW use for OR<1 a 1/OR transformation beforehand). Chromosomal colors are from a self defined palette using the colorRampPalette function in R which makes it look like pointillism art. The real question: Did the previous GWA p value screening miss some important effects? For example the important dot at x=4 and y=4?
The first genomewide association for vitamin D serum levels is already online as the Framingham people told me earlier this day, many thanks!
There are 3 important regions on the above figure figure: around rs1394615, rs1877165 and rs2160595, see also the attached excel sheet fram25ohdexam6or7agesexadj.xls.
What are the reasons that my linkage study arrived at completely different regions? The accompanying BMC Genetics paper even highlights 2 different SNPs: rs1048516 + rs10507577). Anyway, the best region in my opinion is on chromosome 6. Here are the significant SNPs in relation to their neighboring genes: Continue reading First 25OH-D3 GWA online
So far in epidemiology case – control studies are defined by an approach where
… the past histories of patients (the cases) suffering from the condition of interest are compared to the past histories of persons (the controls) who do not have the condition of interest, but who otherwise resemble the cases in such particulars as age and sex ….
I usually explain controls as non-cases in the same overall environment Continue reading When controls are no controls